Page 30 - Flipbook
P. 30
Learning Objectives
By the end of this program, participants will have been
able to learn:
▪ “Timbits” from ASCO 2021
▪ Real world outcomes of ICI and brain metastases in mRCC
▪ Population not studied/excluded from RCTs
▪ Use of SBRT in oligoprogressive mRCC
▪ Canadian perspective?
▪ SBRT + ICI
▪ Can biomarkers predict response rates?
▪ The role of SBRT with ICI in the M1 NED state
